KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) Operating Expenses: 2020-2023

Historic Operating Expenses for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to $75.2 million.

  • AbCellera Biologics' Operating Expenses rose 26.82% to $75.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $275.2 million, marking a year-over-year increase of 2.35%. This contributed to the annual value of $343.6 million for FY2024, which is 24.84% up from last year.
  • As of Q4 2023, AbCellera Biologics' Operating Expenses stood at $75.2 million, which was up 22.35% from $61.5 million recorded in Q3 2023.
  • In the past 5 years, AbCellera Biologics' Operating Expenses registered a high of $91.6 million during Q1 2022, and its lowest value of $6.8 million during Q1 2020.
  • For the 3-year period, AbCellera Biologics' Operating Expenses averaged around $59.6 million, with its median value being $60.4 million (2022).
  • As far as peak fluctuations go, AbCellera Biologics' Operating Expenses spiked by 558.90% in 2021, and later declined by 15.90% in 2023.
  • Over the past 4 years, AbCellera Biologics' Operating Expenses (Quarterly) stood at $47.1 million in 2020, then climbed by 22.59% to $57.8 million in 2021, then climbed by 2.67% to $59.3 million in 2022, then rose by 26.82% to $75.2 million in 2023.
  • Its Operating Expenses was $75.2 million in Q4 2023, compared to $61.5 million in Q3 2023 and $61.4 million in Q2 2023.